BRUSSELS Feb 26 Belgian pharmaceutical group UCB forecast further expansion of revenue and profit this year after its three newer drugs drove earnings by more than expected in 2016.
The company, which specialises in the central nervous system and immunology, said it expected revenue next year to between 4.0 and 4.1 billion euros, recurring core profit (EBITDA) of 0.97-1.01 billion euros and core earnings per share of 2.90-3.20 euros.
19:34 CEO shift at Coca-Cola could usher in more dealmaking to refresh soda giant's growth15
02:11 Murdoch Pounces on Sky as Lower Pound Makes Takeover Cheaper8
22:36 Trump surveys rallygoers on whether Time magazine’s ‘Person of the Year’ is too PC11
15:24 Paris Saint-Germain's Serge Aurier named Ivory Coast Player of the Year12